Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:
“Does adding ipilimumab to atezolizumab plus bevacizumab improve outcomes in first-line advanced HCC?
Adding low-dose ipilimumab (1 mg/kg) did not improve objective response rate (30% vs 27%) or survival outcomes compared to atezolizumab plus bevacizumab alone, and slightly worsened tolerability
Randomized phase 2 study by Merle et al. has recently been published in Lancet Gastroenterology and Hepatology.”
Quoting Erman Akkus, Medical Oncology Fellow at Ankara University, post:
“Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial – Lancet Gastroenterology and Hepatology”
Title: Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
Authors: Philippe Merle, Jean-Frederic Blanc, Karine Le Malicot, Jean-Marie Peron, Vincent Bourgeois, Mohamed Bouattour, Yann Touchefeu, Carole Vitellius, Faiza Khemissa Akouz, Alexandra Heurgué, Paul Girot, Eric Assenat, Eric Nguyen-Khac, Jean-Pierre Bronowicki, Juliette Viaud, Meher Ben Abdelghani, Sylvain Manfredi, Julien Edeline, Jean-Marc Phelip.
Other articles about GI Oncology on OncoDaily.
